Anti-CALRmut/Anti-CD3 Bispecific Antibody JNJ-88549968

Preferred Label : Anti-CALRmut/Anti-CD3 Bispecific Antibody JNJ-88549968;

NCIt synonyms : Anti-CALRmut/CD3 Bispecific Antibody JNJ-88549968; CALRmutxCD3 T-Cell Redirecting Antibody JNJ-88549968; Anti-mutant Calreticulin/Anti-CD3 Bispecific Antibody JNJ-88549968;

NCIt definition : A bispecific antibody directed against both the mutated form of calreticulin (CALRmut; mutCALR) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CALRmut/anti-CD3 bispecific antibody JNJ-88549968 targets and binds to both CALRmut expressed on CALR mutated CD34-positive hematopoietic stem cells (HSCs) and CD3 on T-cells. This results in the cross-linking of CALRmut-expressing tumor cells and T-cells, and induces a cytotoxic T-lymphocyte (CTL) response against CALRmut-expressing tumor cells. CALR mutations, either insertions or deletions in exon 9, result in a frameshift that causes the loss of the KDEL ER retention motif. CALR mutations drive a variety of myeloproliferative neoplasms (MPNs).;

Molecule name : JNJ 88549968; JNJ-88549968;

NCI Metathesaurus CUI : CL1922023;

Détails

Origin ID

C203261;

UMLS CUI

C5907994;

Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- CALR Exon 9 Mutation [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients